Viking Therapeutics, Inc. (NASDAQ:VKTX) CEO Brian Lian Sells 194,490 Shares

Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) CEO Brian Lian sold 194,490 shares of the company's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $42.75, for a total transaction of $8,314,447.50. Following the transaction, the chief executive officer now owns 2,366,570 shares in the company, valued at approximately $101,170,867.50. This trade represents a 7.59 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Viking Therapeutics Stock Performance

Shares of VKTX traded down $0.36 during trading hours on Monday, hitting $42.53. The stock had a trading volume of 2,734,366 shares, compared to its average volume of 2,071,149. The firm has a market capitalization of $4.74 billion, a price-to-earnings ratio of -45.73 and a beta of 0.95. The firm has a 50-day moving average price of $51.93 and a 200 day moving average price of $56.95. Viking Therapeutics, Inc. has a fifty-two week low of $18.14 and a fifty-two week high of $99.41.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last posted its earnings results on Wednesday, October 23rd. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.02. During the same quarter in the previous year, the business earned ($0.23) EPS. As a group, analysts predict that Viking Therapeutics, Inc. will post -0.97 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Blue Trust Inc. acquired a new position in Viking Therapeutics during the third quarter worth $26,000. GAMMA Investing LLC grew its position in shares of Viking Therapeutics by 124.6% in the third quarter. GAMMA Investing LLC now owns 438 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 243 shares during the period. Gilliland Jeter Wealth Management LLC purchased a new stake in shares of Viking Therapeutics during the third quarter worth about $32,000. Stone House Investment Management LLC raised its position in shares of Viking Therapeutics by 66.7% during the 3rd quarter. Stone House Investment Management LLC now owns 500 shares of the biotechnology company's stock worth $32,000 after purchasing an additional 200 shares during the last quarter. Finally, Massmutual Trust Co. FSB ADV lifted its stake in Viking Therapeutics by 84.3% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 553 shares of the biotechnology company's stock valued at $35,000 after buying an additional 253 shares in the last quarter. Hedge funds and other institutional investors own 76.03% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Oppenheimer restated an "outperform" rating and set a $138.00 price target on shares of Viking Therapeutics in a research note on Wednesday, September 25th. StockNews.com raised Viking Therapeutics to a "sell" rating in a research report on Tuesday, October 15th. B. Riley began coverage on Viking Therapeutics in a research report on Friday, November 22nd. They set a "buy" rating and a $109.00 price target for the company. Piper Sandler began coverage on Viking Therapeutics in a report on Monday, December 2nd. They issued an "overweight" rating and a $74.00 price objective on the stock. Finally, William Blair reaffirmed an "outperform" rating on shares of Viking Therapeutics in a report on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, eleven have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $106.75.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.